NASDAQ · CLBT

Cellebrite DI Ltd.

$14.22 +$0.15 (+1.10%) 1D After hours

Key Metrics

$3.51B
Market cap
44.78×
P/E · TTM
$475.68M
Revenue · TTM
$78.33M
Net income
EPS · TTM $0.41
Dividend yield
Free cash flow $160.32M
Beta · 1Y 0.79
EBITDA · TTM $102.55M
Gross margin 84.2%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 29
    The stock moved +11.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 29
  • Apr 10
    From its Mar 6 high, the share price fell 28%.

    Peak close $15.30 on Mar 6; trough close $11.03 on Apr 10. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -28%
  • Apr 10
    The stock moved -11.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 10

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$3.51B
Enterprise value
Shares outstanding249.4M
52-wk range$11.02 – $19.98
Avg volume · 20D928.8K
Net cash
Book value / share$2.55
ExchangeNASDAQ
About Cellebrite DI Ltd.
IPO dateAug 31, 2021
Employees1285

Cellebrite DI Ltd provides AI-powered digital investigative and intelligence solutions that help public and private sector customers transform investigative workflows, make digital data more accessible and actionable, and improve the efficiency of mobile research and application security.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E44.78
P/S7.37
P/FCF21.88
EV/EBITDA
EV/Sales
Graham №$4.86

Profitability

Gross 84.2%
Operating 19.1%
Net 16.5%
FCF 33.7%
ROE / ROIC 19.1% · 37.6%

Financial Health

Current ratio1.56
Quick ratio1.54
Debt / equity
Debt / EBITDA
Net cash
Working capital$206.19M

Cash Flow · TTM

Operating CF $173.54M
Capex −$13.23M
Free cash flow $160.32M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

5.6
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$4.86 vs $14.22
Trades 2.9× above classic defensive value — priced for growth
Fundamentals through 2025-06-30 · computed by TickerWolf from SEC filings